Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors

201612 citationsJournal Article

Authors

Salam Zakko · Bristol Hospital

Glenn L. Gordon · Center for Digestive and Liver Diseases

Uma K. Murthy · SUNY Upstate Medical University

Shahriar Sedghi

Ronald E. Pruitt · Saint Thomas West Hospital

Andrew C. Barrett · Bausch Health (United States)

Enoch Bortey · Bausch Health (United States)

Abstract

Once-daily MG was more efficacious than and as well tolerated as placebo in maintaining UC remission. ClinicalTrials.gov identifiers: NCT00744016 and NCT00767728.

Topics & Keywords

Inflammatory Bowel Disease Microscopic Colitis Celiac Disease Research and Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Postgraduate Medicine

Volume 128, Issue 3, pp. 273-281

DOI: 10.1080/00325481.2016.1152876

Field-Weighted Citation Impact: 1.72